Proxy Votes Now

Home › Funds › First Trust › First Trust NYSE Arca Biotechnology Index Fund

First Trust NYSE Arca Biotechnology Index Fund (FBT) proxy voting record 2025-2026

Fund family: First Trust · Filed by FIRST TRUST EXCHANGE-TRADED FUND (CIK 1329377) · SEC series S000012478

Ticker: FBT (C000033929)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 315 with, 5 against, 0 abstentions (not counted as with management). Shareholder proposals: 1 FOR, 4 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with First Trust as a whole

The same two figures as First Trust’s manager page (194,032 ballot items across 186 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsFirst TrustItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)89.9%29892.8%162,371
Backed environmental and social shareholder proposals at US companiesn/a21.4%2,714

Where this fund voted differently from most First Trust funds

Each ballot item this fund voted is set against the votes of the other First Trust funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted the same way as most First Trust funds on all 209 items where a comparison was possible.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 87.5% of this fund’s 320 such votes could be given a sector; the other 40 (12.5%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care27351.8%
Industrials700.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections1980
Audit-related300
Say-on-Pay290
Compensation270
Corporate Governance203
Capital Structure130
Extraordinary Transactions30
Environment or Climate11
Other Social Issues11

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Moderna, Inc.May 6, 2026$515M50
Moderna, Inc.November 12, 2025$218M20
Corcept Therapeutics IncorporatedMay 21, 2026$149M110
Exelixis, Inc.May 26, 2026$123M140
Amgen Inc.May 19, 2026$115M151
Gilead Sciences, Inc.April 30, 2026$114M153
Illumina, Inc.May 21, 2026$113M110
Biogen Inc.June 9, 2026$110M120

Notable votes against management

MeetingCompanyProposalFundMgmt
May 19, 2026Amgen Inc.Stockholder proposal to require an independent board chairman. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalForAgainst

Search this fund’s votes by company

322 ballot items at 33 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, First Trust NYSE Arca Biotechnology Index Fund (FBT) voted at 33 shareholder meetings of 31 companies, on 322 ballot items in all. Where management made a recommendation, the fund followed it on 98.4% of the items and voted against it 5 times. Its most frequent area of disagreement was corporate governance (3 of its votes against management). It voted on 5 shareholder proposals. It voted FOR the board's own proposals less often than First Trust's funds as a whole (89.9% against 92.8%). It voted the same way as most First Trust funds on every item where a comparison was possible.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of First Trust’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.